Large shareholder sells some Orphazyme shares shortly before vital FDA ruling, general partner denies connection

Sunstone Life Science Ventures is not selling its Orphazyme shares because of the upcoming crucial FDA ruling, general partner Sten Verland tells MedWatch.

Sten Verland, General Partner at Sunstone Life Sciences and board member at Orphazyme. | Photo: Sunstone / PR

As the FDA's response deadline for Orphazyme's drug candidate arimoclomol draws ever closer, Sunstone Life Science Ventures has opted to sell some of its shares in the biotech company.

As of Friday last week, the investment company owned less than five percent of shares in Orphazyme, meaning it dropped below the large shareholder boundary, according to a stock exchange notification released on Tuesday.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

CHMP to remove 100 generic medicines from market

Due to fraudulent clinical trials from a contract research organization, the EMA’s expert committee, the CHMP, is now suspending marketing approval authorizations for around 100 generic drugs on the market.

Further reading

Related articles

Latest news

See all jobs